New: Enable Investor Alerts
Be informed about new publications
New: AI Factsheet

Corporate News meets AI! 
Content analysis and summary

EN GIF 300X250

Asklepios Kliniken · ISIN: DE000A0ETLQ3 · EQS - Company News (29 News)
Country: Germany · Primary market: Germany · EQS NID: 1360091
25 May 2022 10:00AM

Asklepios Kliniken: Sound growth despite challenging environment in first quarter of 2022


DGAP-News: Asklepios Kliniken / Key word(s): Quarterly / Interim Statement/Quarter Results
Asklepios Kliniken: Sound growth despite challenging environment in first quarter of 2022

25.05.2022 / 10:00
The issuer is solely responsible for the content of this announcement.


Asklepios Group: Sound growth despite challenging environment in first quarter of 2022

  • Number of patients up 15.6%
  • Consolidated revenue of EUR 1,276.3 million
  • Well equipped for current uncertainties with central, standardized purchasing strategy

Hamburg, 25 May 2022. In a first quarter dominated by the war in Ukraine and the continuing effects of the coronavirus pandemic, Asklepios made a robust start to a challenging 2022 financial year. The number of inpatients and outpatients cared for increased by 15.6% year-on-year to a total of 836,025 in the first quarter of 2022 (3M 2021: 723,019). In the first three months of the year, the Asklepios Group generated revenue totalling EUR 1,276.3 million (3M 2021: EUR 1,221.0 million).

Despite a challenging environment with rising costs for staff and materials, operating EBITDA was increased to EUR 100.3 million (3M 2021: EUR 89.9 million). The EBITDA margin was 7.9% (3M 2021: 7.4%). Asklepios generated consolidated net income (EAT) of EUR 6.4 million (3M 2021: EUR 0.0 million).

The most important driving factor for the positive development in the first quarter was growth in patient numbers. The number of inpatients increased by 5.5% to 178,463 (3M 2021: 169,190). Outpatient numbers posted significant growth of 18.7% to 657,562 (3M 2022: 553,829).

Kai Hankeln, CEO of Asklepios Kliniken, comments: “Asklepios has broken new ground with expertise and innovation in many areas over the past years. The steadily growing number of patients who place their trust in us every day and feel well cared for in our hospitals backs up this strategy. At the same time, it shows that excellent quality of treatment and healthy business management go hand in hand. In this context, we emphatically welcome the German government’s goal of achieving more efficiency in the healthcare sector with creative new solutions. We are prepared to support the government commission now appointed with professional expertise and personal commitment.”

Asklepios employed an average of 49,814 full-time equivalents in the first quarter of 2022. The staff costs ratio was down slightly on the previous year at 68.0% (3M 2021: 69.4%), while absolute staff costs amounted to EUR 867.7 million (3M 2021: EUR 847.8 million). In the first quarter of 2022, the cost of materials ratio rose to 25.2% (3M 2021: 24.6%) due to increased costs for measures relating to the COVID-19 pandemic.

The Asklepios Group had a stable financial position in the first quarter of 2022: As at 31 March 2022, cash and cash equivalents amounted to EUR 661.8 million (31 December 2021: EUR 647.2 million). The ratio of net debt to EBITDA for the past 12 months, adjusted for IFRS 16, was 3.0x (31 December 2021: 3.1x).

Despite the challenging environment, Asklepios made substantial investments in its roughly 170 healthcare facilities. Investments including subsidies amounted to EUR 51.0 million. At EUR 36.1 million, the share of own funds was 70.8% in the first quarter of 2022 (3M 2021: 77.4%).

Hafid Rifi, Deputy Chairman of the Group management and CFO, says: “Our healthcare system is still facing major challenges: As the pandemic gradually comes to an end, there are now also uncertainties due to the Ukraine war. With our solid economic performance in the first three months of 2022, we are in a position to face these challenges. The current quarterly figures back up our long-term strategy and our strong internal financing capability.”

Asklepios Kliniken is optimistic about the current 2022 financial year. The fourth and five waves of the coronavirus pandemic entailed high incidence rates, but these had no material effect on the utilisation of hospital capacity. At the same time, uncertainty factors such as rising energy and material costs and supply bottlenecks grew as a result of the Ukraine war. In addition to the ongoing shortage of qualified staff, the healthcare market will continue to be influenced by a demanding regulatory environment. Nevertheless, Asklepios anticipates organic revenue growth and a sustainable increase in EBITDA and EAT.

About Asklepios

Asklepios Kliniken is one of the leading private operators of hospitals and healthcare facilities in Germany. The hospital group stands for highly qualified care for its patients, with a clear commitment to medical quality, innovation and social responsibility. On this basis, Asklepios has been developing dynamically since it was founded over 35 years ago. The Group currently has around 170 healthcare facilities throughout Germany. These include acute care hospitals of all different care levels, university hospitals, specialist clinics, psychiatric facilities, forensic institutions, rehabilitation clinics, nursing homes and medical centres. In the 2021 financial year, over 3.5 million patients were treated at the Asklepios Group’s facilities. The company has more than 67,000 employees.

IR contact

Mirjam Constantin
Head of Group ESG & Sustainability/ Manager Investor Relations
Asklepios Kliniken GmbH & Co. KGaA
Debusweg 3 - 61462 Königstein-Falkenstein
Tel.: +49 61 74 90-1166
Fax: +49 61 74 90-1110
ir@asklepios.com

PR contact

Rune Hoffmann
Head of Corporate Communications & Marketing
Asklepios Kliniken GmbH & Co. KGaA
Rübenkamp 226 - 22307 Hamburg
Tel.: +49 40 1818-82 6630
Fax: +49 40 1818-82 6639
presse@asklepios.com

Visit Asklepios online, on Facebook or on YouTube:

www.asklepios.com

www.facebook.com/asklepioskliniken

www.youtube.com/asklepioskliniken



25.05.2022 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de


1360091  25.05.2022 

fncls.ssp?fn=show_t_gif&application_id=1360091&application_name=news&site_id=boersengefluester_html

This publication was provided by our content partner EQS3.

EQS Newswire
via EQS - Newsfeed
EQS Group AG ©2024
(DGAP)
Contact:
Karlstraße 47 D-80333 München
+49 (0) 89 444 430-000

 

SMART * AD
EN GIF 970X250

P R O D U C T   S U G G E S T I O N S

The information presented here has been provided by our content partner EQS-Group. The originator of the news is the respective issuer, the company relating to the news, a publication service provider (press or information agency) which uses the distribution service of EQS to transmit company news to shareholders, investors, investors or interested parties. The original publications and other company-relevant information can be found at eqs-news.com.


The information you can access does not constitute investment advice. The presentation of our cooperation partners, where the implementation of investment decisions would be possible depending on the individual risk profile, is solely at the discretion of the person using the service. We only present companies of which we are convinced that the range of services and customer service will satisfy discerning investors.

If you are considering leverage products, familiarise yourself with the typical characteristics of the financial instruments beforehand. Take the time to determine the risk content of the planned investment before making an investment decision. Bear in mind that a total loss cannot be ruled out with leverage products.

For newcomers to the subject, we offer various options in both the training and the tools section, through which you can train theoretical knowledge and practical experience and thus improve your skills. The offer ranges from participation in webinars to personal mentoring. The range is continuously being expanded.


1 Lab features are usually functionalities that emerge from the think tank of the investor community. In the early stages, these are experimental functionalities whose development process is largely determined by use and the resulting feedback from the community. When integrating external services or functionalities, the functionality can only be guaranteed to the extent that the individual process elements, such as interfaces, interact with each other.